Science Capital

Quantum Motion adds investors in second close of Series C

Quantum Motion adds investors in second close of Series C Image: DCD
Quantum Motion said it has completed a second close of its Series C, adding Imec.ventures, Lansdowne Partners, Sony Innovation Fund, S3 Ventures and Inkef as investors. The company did not disclose the amount added. Its initial close in May was announced as a $160 million round led by DCVC and Kembara. Quantum Motion said the funding will support custom-silicon co-development, use of semiconductor manufacturing pipelines and international expansion, including a Maryland lab.
Sources
DCD
Published by Tech & Business, a media brand covering technology and business. This story was sourced from DCD and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Anthropic nears $15 billion revolver ahead of IPO filing

Anthropic is set to finalize an expansion of its revolving credit facility to $15 billion, according to people familiar with the matter cited by Bloomberg. Morgan Stanley is leading the process, with Goldman Sachs, JPMorgan Chase ...

Bloomberg Technology
Capital Robotics
Capital Robotics

Krafton plans $250 million India investment for AI and robotics

Krafton plans to invest $250 million in India over the next three to four years as it expands into AI and robotics, according to TechCrunch. The PUBG developer's total India investment would exceed $500 million since 2021, the rep...

Techmeme, TechCrunch
Capital AI
Capital AI

Creoir reports Seed investment for offline defence voice AI

Creoir said it raised a Seed investment led by Gungnir Capital as it pursues an ongoing €2 million seed round. The Oulu company said it will use the capital to commercialize its EdgeVUI and Operator Assistant products for European...

EU-Startups
Capital
Capital

Laser Photonics files for best-efforts equity offering

Laser Photonics filed a preliminary S-1 for a best-efforts offering of up to 7,142,857 common shares, with accompanying Series B-1 and B-2 warrants. The prospectus uses an assumed $1.40 price, based on the September 1 Nasdaq clos...

SEC EDGAR
Science
Science

Phase I CTX310 results show one-year lipid reductions

Cleveland Clinic reported 12-month Phase I results for CTX310, a one-time CRISPR-Cas9 infusion for medication-resistant lipid disorders. Among 15 participants, those given the highest dose had LDL cholesterol 52.5% below baseline ...

Medical Xpress
Capital Security
Capital Security

Carrick closes $600 million continuation vehicle for Saviynt

Carrick Capital Partners has closed a $600 million continuation vehicle for identity-security company Saviynt, including a new $255 million investment, dot.LA reported. The vehicle let existing Carrick investors take liquidity or...

dot.la